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KIT mutations are the hallmark of gastrointestinal stromal tumors (GISTs). In a paper recently published
in Nature, Sawyers and colleagues demonstrate that ETV1 collaborates with oncogenic KIT to initiate
a GIST-specific transcriptional program. These results radically alter our view of GIST oncogenesis and
have important implications for diagnosis and therapy.Sarcomas are a diverse group of malig-
nant neoplasms that are unified by the
fact that each diagnostic entity displays
mesenchymal differentiation. Although
they are rare, many sarcoma subtypes
exhibit simple karyotypes that underlie
comparatively simple oncogenetic mech-
anisms that make them accessible to
molecular dissection (Rubin et al., 2009).
Hence, sarcomas have contributed dis-
proportionately to what is known about
mechanisms of oncogenesis versus what
has been learned from more common
tumors.
Gastrointestinal stromal tumors (GISTs)
are the most common type of mesen-
chymal tumor of the gastrointestinal tract
(Rubin et al., 2007). The genetic hallmarks
of GISTs are constitutively activating KIT
or PDGFRA, which encodes platelet-
derived growth factor receptor alpha
(PDGFRa), mutations. These mutations
are present in approximately 85% and
7% of cases, respectively. Inhibition of
KIT and PDGFRa with molecularly tar-
geted inhibitors such as imatinib mesylate
(Gleevec; Novartis Pharmaceuticals) sta-
bilizes metastatic or recurrent GISTs in
approximately 80% of patients; GISTs
are therefore a paradigm for oncogene
addiction and targeted therapy. Although
imatinib is able to control GISTs clinically,
complete tumor regression is seen in
less than 3% of patients, necessitating
lifelong therapy. Furthermore, approxi-
mately 50% of imatinib-treated GIST
patients develop acquired imatinib resis-
tance within 2 years of the initiation of
therapy. Thus, although KIT inhibition has
led to unparalleled therapeutic success inGIST treatment, GIST researchers realize
that KIT inhibition alone is unlikely to
cure GISTs.
It is interesting that the discovery of
KIT mutations in GISTs, undeniably the
most important discovery in the history
of GIST research, came from a researcher
outside of the field; this researcher, Dr.
Yukihiko Kitamura, was mainly focused
on the role of KIT in mast cells and allergic
diseases (Hirota et al., 1998). The dis-
covery followed publications from other
laboratories demonstrating that loss-of-
function Kit mutations led to loss of inter-
stitial cells of Cajal (ICCs), a phenotype
that had gone unnoticed in Kit mutant
mice for decades. ICCs are pacemaker
cells in the gut wall and are responsible
for peristalsis. On the basis of these
data, Kitamura hypothesized that gain-
of-function KIT mutations would result
in ICC tumors. Not only did Kitamura
and colleagues find KIT mutations in
GISTs, but they also proposed that ICCs
were the cells of origin of GISTs. It was
a happy coincidence that imatinib, which
had been developed to inhibit BCR-ABL
kinase, also inhibited KIT. Only 39 months
elapsed between Kitamura’s publication
describing KIT mutations in GISTs and
the report of the first patient successfully
treated with imatinib (Joensuu et al.,
2001). Imatinib is now first-line therapy
for the treatment of GISTs.
Now, approximately 12 years after the
exciting discovery of KIT mutations in
GISTs, Dr. Charles Sawyers, another
relative outsider, has blindsided the field
with an important observation that has
changed the present view of GIST patho-Cancer Cell 18, Ngenesis (Chi et al., 2010). It is even more
impressive that the observation was
made from data that had been generated
in the labs of GIST researchers. While per-
forming an in silico bioinformatics analysis
of publicly available GIST gene expres-
sion datasets for highly expressed tran-
scription factors, the authors discovered
that ETV1 (ETS variant 1), which encodes
a member of the ETS family of transcrip-
tion factors that have been identified as
oncogenes in several other cancers, was
highly expressed in GISTs but not in other
sarcomas. They then demonstrated that
members of an ICC subset known to
give rise to GISTs and ICC hyperplasia
in mouse models expressing constitu-
tively activated Kit also strongly express
Etv1. Moreover, loss of Etv1 in a mouse
Etv1/ knockout model results in com-
plete absence of the same ICC subset
whose members strongly express Etv1.
These results highlight ETV1 as a lineage
and survival marker in ICC and GISTs.
To identify genes that are controlled by
ETV1 in GISTs, the authors performed
gene expression analysis of GIST cell
lines that had been depleted of ETV1
through the use of ETV1-specific shRNAs.
Analysis of genes that were downregu-
lated by ETV1 knockdown demonstrated
a negative correlation with genes that
are upregulated in GIST and the ICC
subset expressing ETV1. This suggested
to the authors that ETV1 unleashes an
ICC- and GIST-specific gene program.
Subsequent analysis by chromatin immu-
noprecipitation and deep sequencing
showed a strong correlation between
ETV1 promoter and enhancer bindingovember 16, 2010 ª2010 Elsevier Inc. 407
Figure 1. ETV1 Collaborates with KIT in GIST Formation
(A) ICC development is directed by both KIT and ETV1. When KIT is constitutively (oncogenically) acti-
vated, ETV1 transcription leads to GIST formation.
(B) At the molecular level, oncogenically activated KIT stimulates MAPK signaling, which prevents protea-
somal degradation of ETV1 and leads to activation of a GIST-specific transcriptional program.
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genes, further supporting the model that
ETV1 is directly responsible for regulating
ICC- and GIST-specific transcription.
From a therapeutic standpoint, it is
exciting that the authors also demon-
strated that shRNA-mediated knockdown
of ETV1 resulted in a reduction of GIST
cell proliferation and decreased tumor
volume in a mouse GIST xenograft model.
Interestingly, tumors that did grow in this
model escaped shRNA-mediated ETV1
silencing, indicating that ETV1 expression
is critically important for GIST tumorigen-
esis. This result and the requirement
for KIT and ETV1 in ICC development sug-
gested that activated KIT and ETV1 might
collaborate to transform ICC or ICC pre-
cursors into GISTs. In support of this
hypothesis, there is evidence that consti-
tutively activated KIT stabilizes ETV1
through MAPK signaling by inhibition of
proteasomal degradation (Figure 1). Sur-
prisingly, constitutively activated KIT and
ETV1 were also shown to collaborate to
transform NIH 3T3 cells. Together these
results demonstrate that constitutively
activated KIT and ETV1 are required for
GIST tumorigenesis.
These studies have important implica-
tions for tumorigenesis in general and
GISTs in particular. They highlight the408 Cancer Cell 18, November 16, 2010 ª20importance of ETV1 as an oncogene by
showing that its involvement extends
beyond Ewing sarcoma, melanoma, and
prostate cancer. The finding that ETV1
and constitutively activated KIT can col-
laborate to transform NIH/3T3 cells sug-
gests that, in the proper context, ETV1
may be an oncogene in other cancers.
Furthermore, ETV1 is rendered oncogenic
in GISTs by a novel mechanism involving
a combination of its high endogenous
expression and stabilization by constitu-
tive KIT activation. More significantly for
GIST patients, ETV1 and MAP kinase
signaling have been highlighted as new
therapeutic targets, either alone or in
combination with imatinib.
Members of a small subset of GISTs
have neither KIT nor PDGFRA mutations
but do contain the BRAF V600E mutation
(Agaram et al., 2008). In light of the find-
ings from Chi et al., it is interesting to
speculate that ETV1 is stabilized in
BRAF V600E mutant GISTs through KIT-
independent MAPK signaling. Moreover,
their results suggest that other mutations
within the MAPK signaling pathway or
even within ETV1 itself might be respon-
sible for driving oncogenesis in GISTs
that do not have KIT or PDGFRA muta-
tions or in GISTs with acquired imatinib
resistance; such GISTs initially respond10 Elsevier Inc.to imatinib but develop imatinib resis-
tance after a minimum of 6 months of
therapy. Approximately 50% of the latter
cases have intra-allelic KIT mutations
that abrogate imatinib binding (Heinrich
et al., 2006), but the mechanism
of resistance in the remaining 50% is
unknown. ETV1 also has the potential to
be an excellent diagnostic marker for
GISTs, especially for the approximately
5% of GISTs that are not immunoreactive
for KIT. Finally, this work began with the
mining of pre-existing datasets, support-
ing the argument that investments in bio-
informatic infrastructure within individual
labs as well as at the institutional,
national, and international levels has the
potential to fully exploit the immense
amount of publicly available data that
have been generated by the recent explo-
sion of genome, transcriptome, and pro-
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